Last reviewed · How we verify

Institut Kassab d'Orthopédie — Portfolio Competitive Intelligence Brief

Institut Kassab d'Orthopédie pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
tranexamic acid (Exacyl®) tranexamic acid (Exacyl®) phase 3 Antifibrinolytic Lysine receptor on plasminogen Oncology, Surgery

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. German Heart Center · 1 shared drug class
  4. Miller Orthopedic Specialists · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut Kassab d'Orthopédie:

Cite this brief

Drug Landscape (2026). Institut Kassab d'Orthopédie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-kassab-d-orthop-die. Accessed 2026-05-16.

Related